Establishment and characterization of SRIK-NKL: a novel CD8+ natural killer/T cell line derived from a patient with leukemic phase of acute lymphoblastic lymphoma.
The distinction between T cells and NK cells is difficult, and becoming more complex, as the diversity of the human lymphocyte repertoire is evident. We report the establishment of a permanent CD8+ NK/T cell line (SRIK-NKL) from a patient with leukemic phase of acute lymphoblastic lymphoma having characteristics of both NK and T cells, and extensively describe its phenotype, including cytotoxic activity, NK cell receptor expression, and other molecules critical for immune function. We further compare SRIK-NKL to other available NK/NK-T cell lines. SRIK-NKL may be useful for studying NK cell development, functions, and modulation, leading to novel strategies for treatment of autoimmune disease, infection, and cancer.
Srivastava
Bejai I S
BI
Department of Laboratory Medicine, Roswell Park Cancer Institute, Buffalo, NY 14263, USA.
Srivastava
Maya D
MD
D015703:Antigens, CD / Q000097:blood; D016827:CD8 Antigens / Q000097:blood*; D018414:CD8-Positive T-Lymphocytes / Q000276:immunology*; D002460:Cell Line; D006801:Humans; D007694:Killer Cells, Natural / Q000276:immunology*; D007938:Leukemia / Q000276:immunology; D008297:Male; D010641:Phenotype; D054198:Precursor Cell Lymphoblastic Leukemia-Lymphoma / Q000276:immunology*
D015703:Antigens, CD; D016827:CD8 Antigens